Founder Mark Kiel comments on today’s news of the acquisition of leading genomics interpretation and curation company, Boston Genetics, and what it means for the race to curate the human genome.
Unlocking the Human Genome: From Sequencing to Curation
In the late 1990s, a groundbreaking race began to sequence the human genome. This ambitious endeavor reached its pinnacle in 2000 when the International Human Genome Sequencing Consortium proudly announced the completion of the entire human genome sequence. This achievement marked the dawn of a new era in medicine, one defined by the promise of precision medicine.
Fast forward two decades, and a new race has emerged in the 2020s—the race to curate the human genome. This race revolves around the aggregation, annotation, and analysis of all available genomic evidence, aiming to enhance the diagnosis and treatment of patients while propelling advancements in precision medicine.
Today, I am proud to announce that Genomenon has acquired Boston Genetics, a premier genomics interpretation and curation company. This strategic move significantly expands our company’s genomic interpretation team and solidifies Genomenon’s position as the frontrunner in the quest to curate the entire human genome.
By combining Genomenon’s AI-powered genomics platform with Boston Genetics’ team of 75 genetic scientists, we have effectively doubled our company’s size and transformed our offerings for both clinical diagnostic and pharmaceutical drug development programs. This acquisition also establishes a new genomics data service arm for Genomenon, enabling us to provide cost-effective variant curation team extensions and workflow optimizations for clinical labs. Notably, Boston Genetics’ existing customers, including top genetic testing labs across the US, will now gain access to Genomenon’s industry-leading AI-driven curation engine and services platform.
Today’s announcement represents the latest milestone in Genomenon’s 10-year evolution and serves as a significant stride forward in the race to curate the human genome. Upon completion, this monumental undertaking will unlock the potential of new precision medicine initiatives, such as newborn sequencing programs and optimized liquid biopsy diagnostics.
We are proud to be at the forefront of this transformative journey, poised to shape the future of medicine through comprehensive genomic curation.
The official press release announcement can be found at this link.
